30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
On Tuesday, June 30, the Department of Justice’s Antitrust Division and the Federal Trade Commissio...
Read More >
The COVID-19 pandemic is one of the biggest threats to the global economy and financial markets that...
Read More >
In an eye-opening opinion letter issued yesterday, the U.S. Department of Labor confirmed that paren...
Read More >
The achievement of legislative consensus in 2018 around a preferred approach to safeguarding U.S. te...
Read More >
The United States Department of Justice released its revised Merger Remedies Manual on September 3, ...
Read More >
In April 2019, the Department of Health and Human Services (HHS) released guidance indicating that a...
Read More >